Although recombinant IFN-α2 and IFN-β were empirically used for the treatment of diseases in humans, such as chronic hepatitis C virus infection and multiple sclerosis, these therapeutics displayed limited efficacies, presumably due to the lack of specificity and the numerous functions of type I IFN. This evidence concerns the gene IFNA2 and chronic hepatitis C virus infection.